Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 801–900 of 4,275
Bacterial intoxication evokes cellular senescence with persistent DNA damage and cytokine signalling
Blazkova, H., Krejcikova, K., Moudry, P., Frisan, T., Hodny, Z., & Bartek, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00862.x · Cited by 99
“Another major result we present is the broad spectrum of pro-inflammatory cytokines produced by the intoxicated cells, a feature recently reported for oncogene induced [24, 44, 45], and replicative senescence [23, 45], and further supported by our own results on drug-induced premature senescence (Novakova, unpublished…”
ResultInfluentialPanebianco, C., Oben, J. A., Vinciguerra, M., & Pazienza, V. (2016) · Clinical and Experimental Medicine · doi:10.1007/s10238-016-0438-x · Cited by 111
Liu, Y., Hawkins, O. E., Su, Y., Vilgelm, A. E., Sobolik, T., Thu, Y., Kantrow, S., Splittgerber, R. C., Short, S., Amiri, K. I., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201378 · Cited by 99
“While senescent cells undergo extended cell cycle arrest, they remain metabolically active and develop SASP after severely damaged DNA accumulates (Coppe et al, 2008; Kuilman et al, 2010).”
Ariffin, H., Azanan, M. S., Abd Ghafar, S. S., Oh, L., Lau, K. H., Thirunavakarasu, T., Sedan, A., Ibrahim, K., Chan, A., Chin, T. F., et al. (2017) · Cancer · doi:10.1002/cncr.30857 · Cited by 99
Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations
Jing, H., Kase, J., Dörr, J. R., Milanovic, M., Lenze, D., Grau, M., Beuster, G., Ji, S., Reimann, M., Lenz, P., et al. (2011) · Genes & Development · doi:10.1101/gad.17620611 · Cited by 99
“Importantly, both OIS and TIS exhibit a senescence-associated secretory phenotype (SASP) (Coppe et al. 2008), an array of predominantly proinflammatory cytokines whose autocrine or paracrine action reportedly reinforces the senescent arrest at least in some settings and whose cross-talk to the…”
BackgroundInfluentialGolde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98
Exosomes as Emerging Pro-Tumorigenic Mediators of the Senescence-Associated Secretory Phenotype
Jakhar, R., & Crasta, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102547 · Cited by 98
“Surprisingly, inactivation of p53 in senescent cells causes hyperexpression of SASP, indicative of negative regulation of SASP by p53 [89].”
BackgroundVenkatachalam, G., Surana, U., & Clément, M.-V. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx684 · Cited by 98
“Moreover, an increase in acidic SA- -Gal activity (Figure 5C) and activation of p16–RB (Figure 5D and E), but not the p21 axis (Supplementary Figure S3A) and secretion of IL-6 (Figure 5F), the most prominent cytokine of the SASPs was detected 48 h after the initial oxidative stress.”
BackgroundInfluentialA new mouse model of frailty: the Cu/Zn superoxide dismutase knockout mouse
Deepa, S. S., Bhaskaran, S., Espinoza, S., Brooks, S. V., McArdle, A., Jackson, M. J., Van Remmen, H., & Richardson, A. (2017) · GeroScience · doi:10.1007/s11357-017-9975-9 · Cited by 98
“other factors) that have potent autocrine and paracrine activities (Coppe et al. 2008), a phenomenon termed the senescence-associated secretory phenotype (SASP).”
BackgroundLevesque, C., & Nelson, P. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030510 · Cited by 107
“For prostate tissue, the DDSP has been profiled in prostate fibroblasts (Bavik et al. 2006; Sun et al. 2012) and epithelial cells (Coppe et al. 2008).”
BackgroundSelf-citationP53 and The Immune Response: 40 Years of Exploration—A Plan for the Future
Levine, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020541 · Cited by 97
“This is termed the “senescence-associated secretory phenotype”, or SASP [25].”
BackgroundInfluentialEpigenetic mechanisms of endothelial dysfunction in type 2 diabetes
Prattichizzo, F., Giuliani, A., Ceka, A., Rippo, M. R., Bonfigli, A. R., Testa, R., Procopio, A. D., & Olivieri, F. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0090-4 · Cited by 97
“Senescent cells can acquire a phenotype that is closely related to the senescence phenotype, named senescence-associated secretory phenotype (SASP) [29].”
BackgroundSenescent human hepatocytes express a unique secretory phenotype and promote macrophage migration
Irvine, K. M., Skoien, R., Bokil, N. J., Melino, M., Thomas, G. P., Loo, D., Gabrielli, B., Hill, M. M., Sweet, M. J., Clouston, A. D., et al. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i47.17851 · Cited by 97
Waaijer, M. E. C., Gunn, D. A., Adams, P. D., Pawlikowski, J. S., Griffiths, C. E. M., van Heemst, D., Slagboom, P. E., Westendorp, R. G. J., & Maier, A. B. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glv114 · Cited by 96
Aging of the Immune System: Research Challenges to Enhance the Health Span of Older Adults
Haynes, L. (2020) · Frontiers in Aging · doi:10.3389/fragi.2020.602108 · Cited by 118
“With increasing age, senescent cells are not cleared as efficiently by the innate immune system, causing them to accumulate and increasing SASP levels (Coppe et al., 2008; Zhu et al., 2014; Xu et al., 2018).”
BackgroundAdvances in Molecular Mechanisms and Treatment of Radiation-Induced Pulmonary Fibrosis
Chen, Z., Wu, Z., & Ning, W. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.09.009 · Cited by 107
Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
Zhu, Y., Prata, L. G. P. L., Gerdes, E. O. W., Netto, J. M. E., Pirtskhalava, T., Giorgadze, N., Tripathi, U., Inman, C. L., Johnson, K. O., Xue, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103912 · Cited by 100
Endothelial cell senescence and thrombosis: Ageing clots
Bochenek, M. L., Schütz, E., & Schäfer, K. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2016.09.019 · Cited by 96
Schneider, L., Pellegatta, S., Favaro, R., Pisati, F., Roncaglia, P., Testa, G., Nicolis, S. K., Finocchiaro, G., & d’Adda di Fagagna, F. (2013) · Stem Cell Reports · doi:10.1016/j.stemcr.2013.06.004 · Cited by 92
“Previous studies established a mechanistic link between the DNA-damage-induced permanent proliferative arrest and cytokine secretion, described as senescence-associated secretory phenotype or SASP, as secretion of IL-6/8 requires ATM and is opposed by p53 (Coppé et al., 2008; Rodier et al., 2009).”
Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
Xu, M., Tchkonia, T., & Kirkland, J. L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.05.015 · Cited by 99
“These SASP components can alter the microenvironment within tissues and affect the function of neighboring cells, which can eventually lead to local and systemic dysfunction.”
InfluentialGeneration and Release of Mitochondrial-Derived Vesicles in Health, Aging and Disease
Picca, A., Guerra, F., Calvani, R., Coelho-Junior, H. J., Bossola, M., Landi, F., Bernabei, R., Bucci, C., & Marzetti, E. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051440 · Cited by 95
“Hence, the analysis of eSASP may offer a unique opportunity to identify senescence biomarkers with a degree of cell-type specificity or arising from different stressors.”
BackgroundInfluentialIRF3 activates RB to authorize cGAS-STING–induced senescence and mitigate liver fibrosis
Wu, Q., Leng, X., Zhang, Q., Zhu, Y., Zhou, R., Liu, Y., Chen, M., Zhang, D., Liu, S., Chen, S., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj2102 · Cited by 115
Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Triana-Martínez, F., Loza, M. I., & Domínguez, E. (2020) · Cells · doi:10.3390/cells9020346 · Cited by 95
“It is well-established that senescence promotes the appearance of tumor cells with a high stemness and promotes EMT [42,81].”
BackgroundInfluentialDolgin, E. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-00750-1 · Cited by 102
Cellular senescence: from growth arrest to immunogenic conversion
Burton, D. G. A., & Faragher, R. (2015) · AGE · doi:10.1007/s11357-015-9764-2 · Cited by 112
“…secretory phenotype When embryonic lung, neonatal foreskin, or adult breast fibroblasts become senescent as a result of DNA damage, they up-regulate and secrete common soluble factors consisting of pro-inflammatory cytokines, growth factors and proteases (Shelton et al. 1999; Coppé et al. 2008).”
BackgroundEnglund, D. A., Zhang, X., Aversa, Z., & LeBrasseur, N. K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111595 · Cited by 94
Emerging roles of RB family: New defense mechanisms against tumor progression
Indovina, P., Marcelli, E., Casini, N., Rizzo, V., & Giordano, A. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24170 · Cited by 100
Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders
Bellei, B., & Picardo, M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100981 · Cited by 93
The role of senescence in cancer development
Mavrogonatou, E., Pratsinis, H., & Kletsas, D. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.018 · Cited by 104
Liu, S., Zheng, Z., Ji, S., Liu, T., Hou, Y., Li, S., & Li, G. (2018) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2018.06.027 · Cited by 95
Liu, H., Zhao, H., & Sun, Y. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.11.004 · Cited by 108
Self-citationThe Chemokine CXCL8 in Carcinogenesis and Drug Response
Gales, D. N., Clark, C. E., Manne, U., & Samuel, T. (2013) · ISRN Oncology · doi:10.1155/2013/859154 · Cited by 114
“Moreover, in response to stress, stromal cells produce CXCL8, which may influence the invasiveness and/or metastatic potential of cancer cells [78, 79].”
BackgroundCellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
“J Exp Clin Cancer Res (2022) 41:360 inflammatory TME driving cancer development [73] and attract myeloid derived suppressor cells that suppress T [264] and NK cells [196] and blocks IL-1α signaling, preventing paracrine senescence in neighboring cancer cells [265].”
BackgroundNovel insights from a multiomics dissection of the Hayflick limit
Chan, M., Yuan, H., Soifer, I., Maile, T. M., Wang, R. Y., Ireland, A., O'Brien, J. J., Goudeau, J., Chan, L. J., Vijay, T., et al. (2022) · eLife · doi:10.7554/elife.70283 · Cited by 99
“The SASP has been shown to play a role in paracrine signaling whereby senescent cells can promote local wound healing and/or drive healthy neighboring cells into senescence ( Acosta et al., 2013 ; Coppé et al., 2006 ; Demaria et al., 2014 ; Coppé et al., 2008 ).”
Primary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93
Cai, L., Liu, H., Huang, F., Fujimoto, J., Girard, L., Chen, J., Li, Y., Zhang, Y.-A., Deb, D., Stastny, V., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01842-7 · Cited by 102
Latorre, E., Birar, V. C., Sheerin, A. N., Jeynes, J. C. C., Hooper, A., Dawe, H. R., Melzer, D., Cox, L. S., Faragher, R. G. A., Ostler, E. L., et al. (2017) · BMC Cell Biology · doi:10.1186/s12860-017-0147-7 · Cited by 93
“This reversal of the age-related decline in splicing factor expression was present for compounds with no discernible SIRT activity (compound 3) as well as those that elevated IL6 and IL8 levels (compounds 2 and 5), indicating that the action of splicing factors is independent of SIRT1 and the SASP.”
BackgroundInfluentialTabibian, J. H., O’Hara, S. P., & Lindor, K. D. (2014) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2014.913189 · Cited by 93
Zhao, Y., Tyshkovskiy, A., Muñoz-Espín, D., Tian, X., Serrano, M., de Magalhaes, J. P., Nevo, E., Gladyshev, V. N., Seluanov, A., & Gorbunova, V. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721160115 · Cited by 92
Hubáčková, S., Kucerova, A., Michlits, G., Kyjacová, L., Reiniš, M., Korolov, O., Bártek, J., & Hodný, Z. (2015) · Oncogene · doi:10.1038/onc.2015.162 · Cited by 105
FASN activity is important for the initial stages of the induction of senescence
Fafián-Labora, J., Carpintero-Fernández, P., Jordan, S. J. D., Shikh-Bahaei, T., Abdullah, S. M., Mahenthiran, M., Rodríguez-Navarro, J. A., Niklison-Chirou, M. V., & O’Loghlen, A. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1550-0 · Cited by 92
Hsp90 inhibitors as senolytic drugs to extend healthy aging
Fuhrmann-Stroissnigg, H., Niedernhofer, L. J., & Robbins, P. D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1475828 · Cited by 92
“kines/chemokines, proteases, and other factors, termed the senescence-associated secretory phenotype (SASP) that can adversely affect not only neighboring cells, but also likely contribute to driving systemic aging [4].”
BackgroundThe KEAP1-NRF2 System in Healthy Aging and Longevity
Matsumaru, D., & Motohashi, H. (2021) · Antioxidants · doi:10.3390/antiox10121929 · Cited by 93
The 3 I’s of immunity and aging: immunosenescence, inflammaging, and immune resilience
Wrona, M. V., Ghosh, R. B., Coll, K., Chun, C., & Yousefzadeh, M. J. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1490302 · Cited by 123
Hendrayani, S.-F., Al-Khalaf, H. H., & Aboussekhra, A. (2013) · Neoplasia · doi:10.1593/neo.13478 · Cited by 92
“Senescent cells also develop a senescence-associated secretory phenotype (SASP), which is characterized by the secretion of a wide range of growth factors, cytokines, extracellular matrix proteins, and degradative enzymes, most of which can alter the local tissue microenvironment [19–21].”
BackgroundZhang, Y., Ravikumar, M., Ling, L., Nurcombe, V., & Cool, S. M. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.01.021 · Cited by 97
“In addition, pro-inflammatory cytokines in the SASP not only activate neutrophils, dendritic cells, and leukocytes recruited by chemotactic cytokines, but also modulate the proliferation and differentiation potential of hMSCs (Klinker et al., 2017).”
BackgroundInfluentialHan, L., Long, Q., Li, S., Xu, Q., Zhang, B., Dou, X., Qian, M., Jiramongkol, Y., Guo, J., Cao, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0506 · Cited by 91
Self-citationRetractedSenescence-Associated Metabolomic Phenotype in Primary and iPSC-Derived Mesenchymal Stromal Cells
Fernandez-Rebollo, E., Franzen, J., Goetzke, R., Hollmann, J., Ostrowska, A., Oliverio, M., Sieben, T., Rath, B., Kornfeld, J.-W., & Wagner, W. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.12.012 · Cited by 90
“Senescent cells secrete a characteristic cocktail of interleukins, chemokines, growth and inflammatory factors, which compose the senescence-associated secretory phenotype (SASP) (Coppé et al., 2008).”
BackgroundInfluentialSASP regulation by noncoding RNA
Panda, A. C., Abdelmohsen, K., & Gorospe, M. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.05.004 · Cited by 86
Noncoding RNA control of cellular senescence
Abdelmohsen, K., & Gorospe, M. (2015) · WIREs RNA · doi:10.1002/wrna.1297 · Cited by 90
“known as SASP (Figure 1, Table 3).(40) IL-1β lowers the levels of miR-24, a repressor of p16/INK4A mRNA translation, leading to a rise in p16 levels.”
BackgroundWnt Antagonist SFRP1 Functions as a Secreted Mediator of Senescence
Elzi, D. J., Song, M., Hakala, K., Weintraub, S. T., & Shiio, Y. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06023-11 · Cited by 89
“This is again in contrast to senescence-associated inflammatory cytokine secretion, which does not require p53 and is restrained by p53 (11).”
BackgroundLawrenson, K., Grun, B., Benjamin, E., Jacobs, I. J., Dafou, D., & Gayther, S. A. (2010) · Neoplasia · doi:10.1593/neo.91948 · Cited by 90
“Senescent cells do not divide but remain metabolically active, and the profile of secreted proteins in senescent cells differs substantially from their nonsenescent counterparts [14].”
BackgroundTargeting cellular senescence in cancer and aging: roles of p53 and its isoforms
Beck, J., Turnquist, C., Horikawa, I., & Harris, C. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa071 · Cited by 92
Cancer secretome and inflammation: The bright and the dark sides of NF-κB
Capece, D., Verzella, D., Tessitore, A., Alesse, E., Capalbo, C., & Zazzeroni, F. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.08.004 · Cited by 90
F4/80+ macrophages contribute to clearance of senescent cells in the mouse postpartum uterus
Egashira, M., Hirota, Y., Shimizu-Hirota, R., Saito-Fujita, T., Haraguchi, H., Matsumoto, L., Matsuo, M., Hiraoka, T., Tanaka, T., Akaeda, S., et al. (2017) · Endocrinology · doi:10.1210/en.2016-1886 · Cited by 90
Aging and radiation: bad companions
Hernández, L., Terradas, M., Camps, J., Martín, M., Tusell, L., & Genescà, A. (2015) · Aging Cell · doi:10.1111/acel.12306 · Cited by 101
“The SASP entails the secretion of factors, such as the proinflammatory cytokines IL (interleukin)-6 and IL-8.”
BackgroundInfluentialAge and Sex: Impact on adipose tissue metabolism and inflammation
Varghese, M., Song, J., & Singer, K. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111563 · Cited by 110
p21 induces a senescence program and skeletal muscle dysfunction
Englund, D. A., Jolliffe, A., Aversa, Z., Zhang, X., Sturmlechner, I., Sakamoto, A. E., Zeidler, J. D., Warner, G. M., McNinch, C., White, T. A., et al. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101652 · Cited by 90
“The SASP is a particularly detrimental feature of cellular senescence, as it can reinforce the senescence program and transmit senescence to otherwise healthy cells, locally and systemically [5,6].”
BackgroundRegulation of senescence escape by TSP1 and CD47 following chemotherapy treatment
Guillon, J., Petit, C., Moreau, M., Toutain, B., Henry, C., Roché, H., Bonichon-Lamichhane, N., Salmon, J. P., Lemonnier, J., Campone, M., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1406-7 · Cited by 90
Biological ageing with HIV infection: evaluating the geroscience hypothesis
Montano, M. A., Oursler, K. K., Xu, K., Sun, Y. V., & Marconi, V. C. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00278-6 · Cited by 109
Self-citationFairfield, H., Dudakovic, A., Khatib, C. M., Farrell, M., Costa, S., Falank, C., Hinge, M., Murphy, C. S., DeMambro, V., Pettitt, J. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1088 · Cited by 88
Cellular Senescence in Intervertebral Disc Aging and Degeneration
Patil, P. R., Niedernhofer, L. J., Robbins, P. D., Lee, J., Sowa, G., & Vo, N. N. (2018) · Current Molecular Biology Reports · doi:10.1007/s40610-018-0108-8 · Cited by 100
Aging and Senescence of Dental Pulp and Hard Tissues of the Tooth
Maeda, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.605996 · Cited by 97
“During the senescence process, senescent cells secrete SASP factors (Coppe et al., 2008) that affect adjacent cells in autocrine or paracrine manners (Acosta et al., 2013; Borodkina et al., 2018).”
BackgroundTargeting the SASP to combat ageing: Mitochondria as possible intracellular allies?
Birch, J., & Passos, J. F. (2017) · BioEssays · doi:10.1002/bies.201600235 · Cited by 89
“The SASP may also promote tumorigenesis, by causingmicroenvironments that favor survival and progression of neoplastic cells and by inducing malignant phenotypes through paracrine mechanisms [19, 24].”
BackgroundAndrade, B., Jara‐Gutiérrez, C., Paz-Araos, M., Vázquez, M. C., Díaz, P., & Murgas, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315182 · Cited by 101
Mechanistic Differences Leading to Infectious and Sterile Inflammation
Behnia, F., Sheller, S., & Menon, R. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12496 · Cited by 89
Bacterial induction of B cell senescence promotes age-related changes in the gut microbiota
Kawamoto, S., Uemura, K., Hori, N., Takayasu, L., Konishi, Y., Katoh, K., Matsumoto, T., Suzuki, M., Sakai, Y., Matsudaira, T., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01145-5 · Cited by 91
Tripathi, U., Nchioua, R., Prata, L. G. P. L., Zhu, Y., Gerdes, E. O. W., Giorgadze, N., Pirtskhalava, T., Parker, E., Xue, A., Espindola-Netto, J. M., et al. (2021) · Aging · doi:10.18632/aging.203560 · Cited by 88
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling
Jeon, H.-M., Kim, J., Cho, H. J., Lee, W. J., Nguyen, D., Kim, S. S., Oh, Y. T., Kim, H., Jung, C., Piñero, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.007 · Cited by 102
Suppression of p16 alleviates the senescence-associated secretory phenotype
(2021) · doi:10.18632/aging.202640 · Cited by 84
“translationally upregulated and secreted into the surrounding microenvironment by senescent cells [14-18].”
BackgroundInfluentialMetabolic requirements of human pro-inflammatory B cells in aging and obesity
Frasca, D., Diaz, A., Romero, M., Thaller, S., & Blomberg, B. B. (2019) · PLOS ONE · doi:10.1371/journal.pone.0219545 · Cited by 86
Catanzaro, J. M., Sheshadri, N., Pan, J.-A., Sun, Y., Shi, C., Li, J., Powers, S., Crawford, H. C., & Zong, W. (2014) · Nature Communications · doi:10.1038/ncomms4729 · Cited by 93
Self-citationCellular Senescence in the Development and Treatment of Cancer
Saretzki, G. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210789941874 · Cited by 87
The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype
Mebratu, Y. A., Soni, S., Rosas, L., Rojas, M. M., Horowitz, J. C., & Nho, R. S. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00124.2023 · Cited by 103
ATF6α regulates morphological changes associated with senescence in human fibroblasts
Druelle, C., Drullion, C., Deslé, J., Martin, N., Saas, L., Cormenier, J., Malaquin, N., Huot, L., Slomianny, C., Bouali, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11505 · Cited by 87
“In addition to be cell cycle-arrested, senescent cells exhibit epigenetic and transcriptomic changes, increase in autophagy, Senescence-Associated β-galactosidase (SA-β-Gal) activity, and pro-inflammatory secretome [5, 6].”
BackgroundThe redox-senescence axis and its therapeutic targeting
Ngoi, N. Y., Liew, A. Q., Chong, S. J. F., Davids, M. S., Clement, M.-V., & Pervaiz, S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102032 · Cited by 88
“ROS have been linked to the activation of NF-κB, one of the major transcription factors that can promote the transcription of SASP components such as IL-6 and IL-8.”
BackgroundInfluentialLewińska, A., Adamczyk‐Grochala, J., Kwasniewicz, E., Deręgowska, A., Semik‐Gurgul, E., Ząbek, T., & Wnuk, M. (2017) · Redox Biology · doi:10.1016/j.redox.2017.08.012 · Cited by 95
Linking JNK Activity to the DNA Damage Response
Picco, V., & Pagès, G. (2013) · Genes & Cancer · doi:10.1177/1947601913486347 · Cited by 93
Shen, W., Liu, L., & Zeng, S. (2018) · Cancer translational medicine · doi:10.4103/ctm.ctm_22_18 · Cited by 98
Sprenger, C. C., Plymate, S. R., & Reed, M. J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25615 · Cited by 87
Type I interferons and related pathways in cell senescence
Frisch, S. M., & MacFawn, I. P. (2020) · Aging Cell · doi:10.1111/acel.13234 · Cited by 85
“…effect of DNA demethylation in p53-null cells and that p53 is important for growth arrest to initiate senescence, and p53 was later found not be required for the induction of the SASP, a feature of stable senescence (Coppe et al., 2008), implicating interferon responses in this maintenance phase.”
BackgroundShort Telomeres in Key Tissues Initiate Local and Systemic Aging in Zebrafish
Carneiro, M. C., Henriques, C. M., Nabais, J., Ferreira, T., Carvalho, T., & Ferreira, M. G. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005798 · Cited by 87
“These cells may be secreting SASP molecules, such as IL-6 and IL-8 which have been described as capable of influencing growth in neighboring cells and epithelial–mesenchymal transition non cell autonomously [36].”
BackgroundDeciphering the role of Nuclear Factor-κB in cellular senescence
Vaughan, S., & Jat, P. S. (2011) · Aging · doi:10.18632/aging.100390 · Cited by 86
“Despite the ability of these factors to promote a malignant phenotype in a paracrine manner, SASP components can bolster senescence in an autocrine manner [53-60], and some even promote the clearance of senescent cells by the immune system [61].”
BackgroundInfluentialGut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis
Jiang, J., Chen, X., Ren, Z., & Zheng, S. (2018) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2018.11.002 · Cited by 107
Buhl, J. L., Selt, F., Hielscher, T., Guiho, R., Ecker, J., Sahm, F., Ridinger, J., Riehl, D., Usta, D., Ismer, B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1965 · Cited by 84
“Upregulation of IL1A/B and IL6 has previously been described in other senescence models in fibroblasts (18, 39–41), human epithelial cells (16), BRAF-transduced human melanocytes (18), and prostate epithelial cancer cells (16), suggesting that IL1B and IL6 are important regulators of OIS.”
BackgroundHIV-associated cellular senescence: A contributor to accelerated aging
Cohen, J., & Torres, C. A. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.12.004 · Cited by 99
“These effects include perturbation of tissue structure by the cleavage of membrane-bound receptors and extracellular matrix proteins (Coppe et al., 2008), stimulation of tissue fibrosis (Laberge et al., 2012), agitation of the stem cell niche (Pricola et al., 2009) and paracrine senescence by…”
Connecting autophagy to senescence in pathophysiology
Young, A. R. J., & Narita, M. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.12.005 · Cited by 107
Androgen Depletion Induces Senescence in Prostate Cancer Cells through Down-regulation of Skp2
Pernicová, Z., Slabáková, E., Kharaishvili, G., Bouchal, J., Král, M., Kunická, Z., Machala, M., Kozubík, A., & Souček, K. (2011) · Neoplasia · doi:10.1593/neo.11182 · Cited by 87
Differential senescence in feto-maternal tissues during mouse pregnancy
Bonney, E. A., Krebs, K., Saade, G., Kechichian, T., Trivedi, J., Huaizhi, Y., & Menon, R. (2016) · Placenta · doi:10.1016/j.placenta.2016.04.018 · Cited by 86
“The signals generated from senescent feto-maternal tissues include a large group of senescence associated factors collectively called as senescence associated secretory phenotype (SASP) [11].”
BackgroundInfluentialMolecular damage in cancer: an argument for mTOR-driven aging
Blagosklonny, M. V. (2011) · Aging · doi:10.18632/aging.100422 · Cited by 90
“Why does aging favors cancer? One explanation is that aging stromal cells secrete factors that promote growth of pre-cancer cells [122, 123, 142-144] and aging is associated with pro-inflammation that favors cancer growth [145-147].”
BackgroundShort-term gain, long-term pain: the senescence life cycle and cancer
Chan, A. S. L., & Narita, M. (2019) · Genes & Development · doi:10.1101/gad.320937.118 · Cited by 80
“The SASP also modulates other key hallmarks of cancers through locally facilitating vascularization (Coppé et al. 2006), epithelial-mesenchymal transition (Coppé et al. 2008; Kuilman et al. 2008), tumor invasion (Kim et al. 2017; He et al. 2018), and cellular plasticity (Ritschka et al. 2017).”
BackgroundNon-cell autonomous effects of the senescence-associated secretory phenotype in cancer therapy.
Saleh, T., Tyutynuk-Massey, L., Cudjoe, E. K., Idowu, M. O., Landry, J. W., & Gewirtz, D. A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00164 · Cited by 85
“, prostate cancer patients treated with mitoxantrone) in association with increased p16INK4a and p21Cip1/Waf1 levels, indicating that senescence and its secretory phase are clinically relevant responses to chemotherapy (18, 68).”
BackgroundMyeloid-derived suppressor cells (MDSC): an important partner in cellular/tissue senescence
Salminen, A., Kauppinen, A., & Kaarniranta, K. (2018) · Biogerontology · doi:10.1007/s10522-018-9762-8 · Cited by 84
Senescence-Associated Pro-inflammatory Cytokines and Tumor Cell Plasticity
Vernot, J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00063 · Cited by 86
“, 2001), collectively known as the senescenceassociated secretory phenotype (SASP) (Coppé et al., 2008).”
BackgroundInfluentialGenetics of melanoma progression: the rise and fall of cell senescence
Bennett, D. C. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12422 · Cited by 85
“IL6 and IL1; also including proteases such as MMP2, angiogenic factors like VEGFs, and other growth factors (Coppé et al., 2008; Kuilman et al., 2008).”
BackgroundThe role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
Shi, C., Qin, K., Lin, A., Jiang, A., Cheng, Q., Liu, Z., Zhang, J., & Luo, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02469-0 · Cited by 85
Aging and cancer cell biology, 2009
Campisi, J., & Yaswen, P. (2009) · Aging Cell · doi:10.1111/j.1474-9726.2009.00475.x · Cited by 85
“Coppe et al. (2008) provided the first extensive characterization of the senescence-associated secretory phenotype (SASP).”
BackgroundSelf-citationMenendez, J. A., Cufí, S., Oliveras-Ferraros, C., Martin-Castillo, B., Joven, J., Vellon, L., & Vazquez-Martin, A. (2011) · Aging · doi:10.18632/aging.100407 · Cited by 85
“Senescent cells accumulate in various tissues and organs with aging and have been hypothesized to disrupt tissue structure and function [120-122].”
BackgroundZhao, X., Liu, Y., Jia, P., Cheng, H., Wang, C., Chen, S., Huang, H., Han, Z., Han, Z., Marycz, K., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02262-4 · Cited by 91
Blocking negative effects of senescence in human skin fibroblasts with a plant extract
Lämmermann, I., Terlecki-Zaniewicz, L., Weinmüllner, R., Schosserer, M., Dellago, H., de Matos Branco, A. D., Autheried, D., Sevcnikar, B., Kleissl, L., Berlin, I., et al. (2018) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-018-0023-5 · Cited by 84
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.